

Tailoring Journeys: Customised Care With CDK4/6 Inhibitors in HR+ HER2- Metastatic Breast Cancer

Wednesday, 15 May 2024

18:30–19:30 CEST

Hamburg Hall, Hub 27

Messe Berlin, Berlin

HYBRID 



OVERVIEW

How can we address patient needs for an optimal customised approach in the treatment of HR+/HER2- metastatic breast cancer?

Join our distinguished panel of experts as they discuss key data for CDK4/6 inhibitors and gain expert guidance on the implementation of shared decision-making to optimise the needs of patients with HR+/HER2- metastatic breast cancer.

FACULTY



Richard Finn, MD
Los Angeles, United States



**Antonio Llombart-Cussac
MD, PhD**
Valencia, Spain



Renate Haidinger
Hohenbrunn, Germany

AGENDA

18:30 – 18:35 Welcome and Introduction
Richard Finn

18:35 – 18:45 Embarking on a Patient-Centric Journey:
What Matters the Most to Patients
With MBC
Renate Haidinger

18:45 – 19:00 An Encompassing Journey:
Shaping Clinical Decisions
Richard Finn

19:00 – 19:15 A Unique Journey:
Personalising Approaches
Antonio Llombart-Cussac

19:15 – 19:25 Panel Discussion
and Audience Q&A
All Faculty

19:25 – 19:30 Closing Remarks
Richard Finn